American International Group, Inc. Arbutus Biopharma Corp Transaction History

American International Group, Inc.

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$2.26 - $2.92 $1,211 - $1,565	-536 Reduced 0.85%	62,439 $161,000
Q4 2023 Feb 13, 2024	BUY	$1.69 - $2.54 $1,154 - $1,734	683 Added 1.1%	62,975 $157,000
Q3 2023 Nov 13, 2023	BUY	$1.9 - $2.27 $4,206 - $5,025	2,214 Added 3.69%	62,292 $126,000
Q2 2023 Aug 04, 2023	BUY	$2.24 - $3.06 $11,751 - $16,052	5,246 Added 9.57%	60,078 $138,000
Q1 2023 May 12, 2023	BUY	$2.23 - $3.1 $2,432 - $3,382	1,091 Added 2.03%	54,832 $166,000
Q4 2022 Feb 10, 2023	BUY	$1.91 - $2.85 $4,721 - $7,045	2,472 Added 4.82%	53,741 $125,000
Q3 2022 Nov 14, 2022	BUY	$1.88 - $2.88 $1,363 - $2,088	725 Added 1.43%	51,269 $98,000
Q2 2022 Aug 12, 2022	BUY	$1.98 - $3.17 $10,517 - $16,839	5,312 Added 11.74%	50,544 $137,000
Q1 2022 May 13, 2022	BUY	$2.42 - $3.98 $6,129 - $10,081	2,533 Added 5.93%	45,232 $135,000
Q4 2021 Feb 11, 2022	SELL	$3.11 - $4.61 $3,974 - $5,891	-1,278 Reduced 2.91%	42,699 $166,000
Q3 2021 Nov 12, 2021	BUY	$2.65 - $4.62 $567 - $988	214 Added 0.49%	43,977 $189,000
Q2 2021 Aug 13, 2021	BUY	$2.5 - $3.51 $109,407 - $153,608	43,763 New	43,763 $133,000
Q2 2019 Aug 13, 2019	SELL	$1.46 - $4.44 $32,873 - $99,971	-22,516 Closed	0 $0
Q1 2019 May 06, 2019	SELL	$3.41 - $4.57 $2,485 - $3,331	-729 Reduced 3.14%	22,516 $81,000
Q4 2018 Feb 13, 2019	SELL	$3.5 - $9.66 $630 - $1,738	-180 Reduced 0.77%	23,245 $89,000
Q3 2018 Nov 09, 2018	BUY	$7.85 - $12.35 $3,320 - $5,224	423 Added 1.84%	23,425 $221,000
Q2 2018 Aug 08, 2018	BUY	$5.0 - $7.35 $115,010 - $169,064	23,002 New	23,002 $168,000

155

99.5M

2.31M

525K

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $478M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

Stay updated on American International Group, Inc. with notifications on news.